Applying the so-called 'Actavis Questions' (further to the Supreme Court decision in Actavis v Eli Lilly), the Court of Appeal reached a different conclusion from the Patents Court on the issue of…
The Court of Appeal overturned the Patent Court's first instance decision concerning the validity of one of ICOS’s patents (licensed to Eli Lilly) covering a 1 to 5mg dosage form of tadalafil (Cialis…
In a case concerning two patents in the field of underwater mine clearance, the Court of Appeal upheld the Patents Court's decision that claims 1 and 2 of the 576 Patent were invalid for obviousness,…
The Court of Appeal dismissed an appeal filed by Cubist against the Patents Court decision that one of its patents relating to antibiotic daptomycin was invalid for obviousness. The Court of Appeal…
The Court of Appeal decided to stay appeal proceedings and refer a question to the CJEU concerning the circumstances in which an active ingredient that is a member of a class of compounds which fall…
Following the Court of Appeal's decision that two of Regeneron's patents were valid and infringed, it refused to grant Kymab permission to appeal to the Supreme Court, but held that the injunction…
The Court of Appeal overturned the Patents Court decision to strike out Glaxo Group’s (GSK’s) claim for an Arrow declaration in proceedings concerning a number of patents relating to dry powder…
The Court ordered a twelve month stay of the injunction granted when it found one of Boston’s patents concerning a transcatheter heart valve (THV) valid and infringed by Edwards’ medical device, in…
The Supreme Court concluded that it was appropriate for it to reformulate the so-called Improver (or 'Protocol') questions, which provide guidance as to whether a variant is immaterial where there is…
